BCR-ABL controls many signaling pathways some of which are essential for resistance to TKI-induced apoptosis: PI3K/AKT [192], JAK/STAT [193,194], or Ras/MEK/ERK [195] and represent therefore good secondary targetable candidates to reach a cure for CML [196]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.